Short answer
TG THERAPEUTICS, INC. (TGTX) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $162M (up 92.8% year over year) with net income of $391M.
Q3 2025 key financials · XBRL
- Revenue
- $162M
- +92.8% YoY · +14.6% QoQ
- Net income
- $391M
- +9974.6% YoY · +1286.8% QoQ
- Operating margin
- 18.2%
- EPS (diluted)
- $2.42
- +7966.7% YoY · +1323.5% QoQ
Source: XBRL data from the TG THERAPEUTICS, INC. (TGTX) Q3 2025 10-Q on SEC EDGAR. USD.
TG THERAPEUTICS, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: post-marketing requirements for BRIUMVI including long-term safety studies and pediatric/pregnancy evaluation triggered by FDA approval conditions
- Most updated risk: commercialization challenges due to expanding global operations; BRIUMVI launched in Europe Feb 2024 with risks in third-party partnerships impacting sales control
- Key regulatory risk: ongoing compliance with cGMP, GCP, GLP and risk of FDA-imposed labeling changes, REMS, product recalls, or approval suspension after unforeseen side effects
- Near-term operational risk: intense competition from larger pharma with greater R&D and commercialization resources could limit BRIUMVI market share and revenues
- Financial risk: reimbursement challenges and pricing pressures from U.S. government healthcare programs like Medicaid rebates and 340B discounts may reduce net pricing and revenues
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TG THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.